<?xml version="1.0" encoding="UTF-8"?>
<p>The survival benefits of initiation of combination antiretroviral therapy (cART) in co-infected patients, particularly those with low CD4+ T-cell counts, have been well documented [
 <xref rid="pone.0192030.ref004" ref-type="bibr">4</xref>, 
 <xref rid="pone.0192030.ref005" ref-type="bibr">5</xref>]. However, although cART has been reported to reduce the risk of developing active TB among HIV infected persons by 67% [
 <xref rid="pone.0192030.ref006" ref-type="bibr">6</xref>], co-infected individuals have a heightened risk of mortality [
 <xref rid="pone.0192030.ref007" ref-type="bibr">7</xref>, 
 <xref rid="pone.0192030.ref008" ref-type="bibr">8</xref>]. Furthermore, HIV infected individuals on cART remain at a higher risk of developing active TB than HIV uninfected individuals [
 <xref rid="pone.0192030.ref009" ref-type="bibr">9</xref>–
 <xref rid="pone.0192030.ref011" ref-type="bibr">11</xref>]. Studies conducted in both low and high income countries have determined that the risk of active TB does not return to background rates despite long term ART [
 <xref rid="pone.0192030.ref002" ref-type="bibr">2</xref>, 
 <xref rid="pone.0192030.ref003" ref-type="bibr">3</xref>, 
 <xref rid="pone.0192030.ref011" ref-type="bibr">11</xref>–
 <xref rid="pone.0192030.ref013" ref-type="bibr">13</xref>].
</p>
